Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Agency
National Institutes of Health
Posted
Oct 14, 2026
Due Date
Sep 25, 2029
Description
<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). Based on the proposed research, applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). This is a re-issuance of <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html">PAR-23-284</a>. The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must reach a translational human endpoint within the project period of the grant. </p>
AI Summary
Estimated Funding: 1,400,000 | Agency: National Institutes of Health
Details
- Notice ID
- 360541
- Solicitation Number
- PAR-28-022
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health